1. Scrip
  2. >>Rare Diseases

Sobi Eyes International Expansion With Growing Late-Stage Pipeline

Revenues Grew By 8% In 2020

 
• By John Davis

Sobi is extending its reach in international markets including Russia and China and expects its late-stage R&D pipeline to drive growth.

Shanghai skyline
China Is A Priority Market • Source: Shutterstock

Swedish Orphan Biovitrum AB (Sobi) says it has earmarked international expansion as a key priority after a busy 2020 which saw its late-stage R&D pipeline grow through partnerships with two US biotechs, Selecta Biosciences, Inc. and Apellis Pharmaceuticals, Inc. and the approval extension for the thrombopoietin receptor agonist Doptelet (avatrombopag) in early 2021 in the EU. 

However, CEO Guido Oelkers cautioned that Sobi could face headwinds in 2021 from the COVID-19 pandemic and appreciation of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.